Abstract
Serotonin is a neuromediator, well-know for its implication in mood regulation, anxiety, depression and, insomnia as well as in normal human function such as sleep, sexual activity and appetite. In this way, serotonin (5-hydroxytryptamine, 5-HT) is one of the most attractive targets for medicinal chemists and pharmaceutical companies. Among 5-HTRs, the 5-HT1A subtype is the best studied, and it is generally accepted that it is involved in psychiatric disorders such as anxiety and depression. Several structurally different compounds are known to bind 5-HT1A receptor sites such as aminotetralins, ergolines, arylpiperazines, indolylalkylamines, aporphines and aryloxyalkyl-amines.
Keywords: serotonin, neurotransmitter, g protein-coupled receptors, median raphe nucleus (mrn), ohdpat, enantioselectivity, indolylalkylamines, ergolines, aporphines, qsar
Current Medicinal Chemistry
Title: Derivatives as 5HT1A Receptor Ligands-Past and Present
Volume: 12 Issue: 15
Author(s): G. Caliendo, V. Santagada, E. Perissutti and F. Fiorino
Affiliation:
Keywords: serotonin, neurotransmitter, g protein-coupled receptors, median raphe nucleus (mrn), ohdpat, enantioselectivity, indolylalkylamines, ergolines, aporphines, qsar
Abstract: Serotonin is a neuromediator, well-know for its implication in mood regulation, anxiety, depression and, insomnia as well as in normal human function such as sleep, sexual activity and appetite. In this way, serotonin (5-hydroxytryptamine, 5-HT) is one of the most attractive targets for medicinal chemists and pharmaceutical companies. Among 5-HTRs, the 5-HT1A subtype is the best studied, and it is generally accepted that it is involved in psychiatric disorders such as anxiety and depression. Several structurally different compounds are known to bind 5-HT1A receptor sites such as aminotetralins, ergolines, arylpiperazines, indolylalkylamines, aporphines and aryloxyalkyl-amines.
Export Options
About this article
Cite this article as:
Caliendo G., Santagada V., Perissutti E. and Fiorino F., Derivatives as 5HT1A Receptor Ligands-Past and Present, Current Medicinal Chemistry 2005; 12 (15) . https://dx.doi.org/10.2174/0929867054367220
DOI https://dx.doi.org/10.2174/0929867054367220 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stimulated CB1 Cannabinoid Receptor Inducing Ischemic Tolerance and Protecting Neuron from Cerebral Ischemia
Central Nervous System Agents in Medicinal Chemistry Could Better Phenotyping Small Vessel Disease Provide New Insights into Alzheimer Disease and Improve Clinical Trial Outcomes?
Current Alzheimer Research Editorial: Unjustified Concerns about Energy Drinks
Current Drug Abuse Reviews DeepInteract: Deep Neural Network Based Protein-Protein Interaction Prediction Tool
Current Bioinformatics NMDA Receptor Antagonists: Repositioning of Memantine as a Multitargeting Agent for Alzheimer's Therapy
Current Pharmaceutical Design Meet Our Editor
Current Gene Therapy Dendrimers as Biopharmaceuticals: Synthesis and Properties
Current Topics in Medicinal Chemistry Managing Erectile Dysfunction in Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Seeing Early Signs of Alzheimer's Disease Through the Lens of the Eye
Current Alzheimer Research Adaptation to Traumatic Stress: Resilient Traits, Resources, and Trajectories of Outcomes
Current Psychiatry Reviews The Involvement of Post-Translational Modifications in Alzheimer's Disease
Current Alzheimer Research Interventions to Improve the Implementation of Evidence Based Practices in Women Care
Current Women`s Health Reviews Commentary: Fatal French Clinical Trial: What Can We Learn from What Went Wrong?
CNS & Neurological Disorders - Drug Targets Systemic Administration of Fluoro-Gold for the Histological Assessment of Vascular Structure, Integrity and Damage
Current Neurovascular Research Targeting Alpha-Synuclein for the Treatment of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets How Much Value Would a Treatment for Alzheimer’s Disease Offer? Cost-Effectiveness Thresholds for Pricing a Disease-Modifying Therapy
Current Alzheimer Research Employing New Cellular Therapeutic Targets for Alzheimers Disease: A Change for the Better?
Current Neurovascular Research The Wnt Pathway in Mood Disorders
Current Neuropharmacology Review of Theoretical Models to Study Natural Products with Antiprotozoal Activity
Current Drug Targets Ca2+ Mediates the Adhesion of Breast Cancer Cells in Self-Assembled Multifunctional Microfluidic Chip Prepared with Carbohydrate Beads
Micro and Nanosystems